Insulet Corporation

Fundamentals7.0
Price Action6.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • High gross margin
  • Significant leverage
  • Elevated multiples

AI
AI Summary

6.0

PODD's high‑margin, recurring‑revenue Omnipod franchise provides strong FCF and a meaningful cash buffer, but recent Omnipod 5 quality issues, securities inquiries, rising short interest and significant leverage convert the stock into an execution- and legal‑risk trade that can prompt rapid valuation compression if remediation stalls. Actionable stance: hold/watch until remediation delivers normalized new‑starts and consumables cadence, no material regulatory enforcement or large legal exposures are disclosed, or the company demonstrably reduces leverage/reevaluates guidance.

CashResilience
LegalRisk
ExecutionWatch‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • High gross margin
  • Significant leverage
  • Elevated multiples

PODD delivers strong margins, returns and free cash flow but faces high operating costs, material leverage and rich valuation multiples that limit upside.

cashflow
overvalued

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below SMA
  • Defense at support
  • Elevated volatility

PODD closed at $227.10, trading roughly 4.7% below its last-month SMA (~$238.35) and inside a volatile last-month range (~$219.84–$251.50) where buyers have recently defended the $219.8 area but the short-term bias remains bearish until price reclaims the SMA and breaks above $251.50.

Bearish
Watchlist
Support Level: $219.84
Resistance Level: $251.50

~14% trading range over the last month signals elevated short-term volatility

Sentiment & News

7.0

Key News Insights:

  • Device correction
  • Rising short interest
  • Institutional buys

Insulet shows strong Omnipod 5 commercial and international momentum but faces a material setback from a March device correction linked to serious adverse events, triggering securities‑fraud probes, rising short interest and a sharp stock pullback.

Regulatory
Growth

Near‑term downside risk is elevated as regulatory, legal and safety issues pressure sentiment despite solid product traction and growth potential